View Financial HealthBIOTON 배당 및 자사주 매입배당 기준 점검 0/6BIOTON 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Mar 05Full year 2025 earnings released: EPS: zł0.04 (vs zł0.18 loss in FY 2024)Full year 2025 results: EPS: zł0.04 (up from zł0.18 loss in FY 2024). Revenue: zł282.5m (up 36% from FY 2024). Net income: zł3.39m (up zł19.1m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.공시 • Jan 29+ 4 more updatesBIOTON S.A. to Report Q4, 2025 Results on Feb 27, 2026BIOTON S.A. announced that they will report Q4, 2025 results on Feb 27, 2026Reported Earnings • Nov 02Third quarter 2025 earnings released: EPS: zł0.049 (vs zł0.039 loss in 3Q 2024)Third quarter 2025 results: EPS: zł0.049 (up from zł0.039 loss in 3Q 2024). Revenue: zł72.7m (up 73% from 3Q 2024). Net income: zł4.20m (up zł7.57m from 3Q 2024). Profit margin: 5.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.Reported Earnings • Sep 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł79.9m (up 58% from 2Q 2024). Net income: zł3.24m (up zł6.03m from 2Q 2024). Profit margin: 4.1% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.New Risk • Sep 18New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.공시 • May 20BIOTON S.A., Annual General Meeting, Jun 23, 2025BIOTON S.A., Annual General Meeting, Jun 23, 2025.공시 • Apr 22+ 2 more updatesBIOTON S.A. to Report First Half, 2025 Results on Aug 28, 2025BIOTON S.A. announced that they will report first half, 2025 results on Aug 28, 2025Reported Earnings • Feb 07Full year 2024 earnings released: zł0.18 loss per share (vs zł0.026 profit in FY 2023)Full year 2024 results: zł0.18 loss per share (down from zł0.026 profit in FY 2023). Revenue: zł207.8m (up 14% from FY 2023). Net loss: zł15.7m (down zł17.9m from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 10Third quarter 2024 earnings released: zł0.039 loss per share (vs zł0.051 loss in 3Q 2023)Third quarter 2024 results: zł0.039 loss per share (improved from zł0.051 loss in 3Q 2023). Revenue: zł42.0m (down 17% from 3Q 2023). Net loss: zł3.37m (loss narrowed 24% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł50.6m (up 3.2% from 2Q 2023). Net loss: zł2.79m (down 296% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.Reported Earnings • May 19First quarter 2024 earnings released: zł0.059 loss per share (vs zł0.002 loss in 1Q 2023)First quarter 2024 results: zł0.059 loss per share (further deteriorated from zł0.002 loss in 1Q 2023). Revenue: zł37.5m (up 9.0% from 1Q 2023). Net loss: zł5.04m (loss widened zł4.91m from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.공시 • May 10BIOTON S.A., Annual General Meeting, Jun 06, 2024BIOTON S.A., Annual General Meeting, Jun 06, 2024.Reported Earnings • Mar 31Full year 2023 earnings releasedFull year 2023 results: Revenue: zł181.6m (down 22% from FY 2022). Net income: zł2.28m (up 60% from FY 2022). Profit margin: 1.3% (up from 0.6% in FY 2022). The increase in margin was driven by lower expenses.공시 • Feb 02+ 3 more updatesBIOTON S.A. to Report First Half, 2024 Results on Aug 27, 2024BIOTON S.A. announced that they will report first half, 2024 results on Aug 27, 2024New Risk • Nov 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (zł322.8m market cap, or US$77.1m).Reported Earnings • Nov 02Third quarter 2023 earnings released: zł0.051 loss per share (vs zł0.023 loss in 3Q 2022)Third quarter 2023 results: zł0.051 loss per share (further deteriorated from zł0.023 loss in 3Q 2022). Revenue: zł50.7m (down 12% from 3Q 2022). Net loss: zł4.42m (loss widened 128% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: zł0.017 (vs zł0.017 in 2Q 2022)Second quarter 2023 results: EPS: zł0.017 (in line with 2Q 2022). Revenue: zł49.0m (up 2.1% from 2Q 2022). Net income: zł1.42m (down 2.8% from 2Q 2022). Profit margin: 2.9% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 31First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.공시 • May 26BIOTON S.A., Annual General Meeting, Jun 21, 2023BIOTON S.A., Annual General Meeting, Jun 21, 2023, at 10:00 Central European Standard Time.Reported Earnings • May 04First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.공시 • Feb 03+ 3 more updatesBIOTON S.A. to Report First Half, 2023 Results on Aug 31, 2023BIOTON S.A. announced that they will report first half, 2023 results on Aug 31, 2023Reported Earnings • Nov 06Third quarter 2022 earnings released: zł0.023 loss per share (vs zł0.054 profit in 3Q 2021)Third quarter 2022 results: zł0.023 loss per share (down from zł0.054 profit in 3Q 2021). Revenue: zł57.5m (up 20% from 3Q 2021). Net loss: zł1.93m (down 142% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 02Second quarter 2022 earnings released: EPS: zł0.017 (vs zł0.043 in 2Q 2021)Second quarter 2022 results: EPS: zł0.017 (down from zł0.043 in 2Q 2021). Revenue: zł48.1m (up 32% from 2Q 2021). Net income: zł1.46m (down 60% from 2Q 2021). Profit margin: 3.0% (down from 10.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.공시 • Jun 01BIOTON S.A., Annual General Meeting, Jun 30, 2022BIOTON S.A., Annual General Meeting, Jun 30, 2022, at 10:00 Central European Standard Time.분석 기사 • Mar 21We Think BIOTON (WSE:BIO) Is Taking Some Risk With Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 45% share price gain to zł5.50, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 32x in the Biotechs industry in Poland. Total returns to shareholders of 11% over the past three years.Reported Earnings • Nov 03Third quarter 2021 earnings released: EPS zł0.054 (vs zł0.028 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł47.8m (up 10% from 3Q 2020). Net income: zł4.61m (up 93% from 3Q 2020). Profit margin: 9.6% (up from 5.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.분석 기사 • Sep 08The Strong Earnings Posted By BIOTON (WSE:BIO) Are A Good Indication Of The Strength Of The BusinessEven though BIOTON S.A.'s ( WSE:BIO ) recent earnings release was robust, the market didn't seem to notice. We think...Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS zł0.043 (vs zł0.08 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł36.5m (down 27% from 2Q 2020). Net income: zł3.67m (down 46% from 2Q 2020). Profit margin: 10.0% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 8% per year.Reported Earnings • Apr 19Full year 2020 earnings released: EPS zł0.40 (vs zł1.48 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł221.8m (up 9.8% from FY 2019). Net income: zł33.9m (up zł160.6m from FY 2019). Profit margin: 15% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 22New 90-day high: zł4.64The company is up 1.0% from its price of zł4.57 on 24 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 13% over the same period.공시 • Jan 30+ 2 more updatesBIOTON S.A. to Report Q3, 2021 Results on Oct 29, 2021BIOTON S.A. announced that they will report Q3, 2021 results on Oct 29, 2021Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS zł0.028The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: zł43.4m (down 3.3% from 3Q 2019). Net income: zł2.39m (up zł9.73m from 3Q 2019). Profit margin: 5.5% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Is New 90 Day High Low • Sep 24New 90-day low: zł4.16The company is down 11% from its price of zł4.65 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 44% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BIO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BIO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장BIOTON 배당 수익률 vs 시장BIO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BIO)n/a시장 하위 25% (PL)2.6%시장 상위 25% (PL)7.2%업계 평균 (Biotechs)2.2%분석가 예측 (BIO) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BIO 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BIO 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BIO 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BIO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YPL 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 08:10종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BIOTON S.A.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Vladimira UrbankovaErste Group Bank AGOvidiu FerWood & Company
Reported Earnings • Mar 05Full year 2025 earnings released: EPS: zł0.04 (vs zł0.18 loss in FY 2024)Full year 2025 results: EPS: zł0.04 (up from zł0.18 loss in FY 2024). Revenue: zł282.5m (up 36% from FY 2024). Net income: zł3.39m (up zł19.1m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
공시 • Jan 29+ 4 more updatesBIOTON S.A. to Report Q4, 2025 Results on Feb 27, 2026BIOTON S.A. announced that they will report Q4, 2025 results on Feb 27, 2026
Reported Earnings • Nov 02Third quarter 2025 earnings released: EPS: zł0.049 (vs zł0.039 loss in 3Q 2024)Third quarter 2025 results: EPS: zł0.049 (up from zł0.039 loss in 3Q 2024). Revenue: zł72.7m (up 73% from 3Q 2024). Net income: zł4.20m (up zł7.57m from 3Q 2024). Profit margin: 5.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.
Reported Earnings • Sep 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł79.9m (up 58% from 2Q 2024). Net income: zł3.24m (up zł6.03m from 2Q 2024). Profit margin: 4.1% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.
New Risk • Sep 18New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
공시 • May 20BIOTON S.A., Annual General Meeting, Jun 23, 2025BIOTON S.A., Annual General Meeting, Jun 23, 2025.
공시 • Apr 22+ 2 more updatesBIOTON S.A. to Report First Half, 2025 Results on Aug 28, 2025BIOTON S.A. announced that they will report first half, 2025 results on Aug 28, 2025
Reported Earnings • Feb 07Full year 2024 earnings released: zł0.18 loss per share (vs zł0.026 profit in FY 2023)Full year 2024 results: zł0.18 loss per share (down from zł0.026 profit in FY 2023). Revenue: zł207.8m (up 14% from FY 2023). Net loss: zł15.7m (down zł17.9m from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 10Third quarter 2024 earnings released: zł0.039 loss per share (vs zł0.051 loss in 3Q 2023)Third quarter 2024 results: zł0.039 loss per share (improved from zł0.051 loss in 3Q 2023). Revenue: zł42.0m (down 17% from 3Q 2023). Net loss: zł3.37m (loss narrowed 24% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł50.6m (up 3.2% from 2Q 2023). Net loss: zł2.79m (down 296% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 19First quarter 2024 earnings released: zł0.059 loss per share (vs zł0.002 loss in 1Q 2023)First quarter 2024 results: zł0.059 loss per share (further deteriorated from zł0.002 loss in 1Q 2023). Revenue: zł37.5m (up 9.0% from 1Q 2023). Net loss: zł5.04m (loss widened zł4.91m from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
공시 • May 10BIOTON S.A., Annual General Meeting, Jun 06, 2024BIOTON S.A., Annual General Meeting, Jun 06, 2024.
Reported Earnings • Mar 31Full year 2023 earnings releasedFull year 2023 results: Revenue: zł181.6m (down 22% from FY 2022). Net income: zł2.28m (up 60% from FY 2022). Profit margin: 1.3% (up from 0.6% in FY 2022). The increase in margin was driven by lower expenses.
공시 • Feb 02+ 3 more updatesBIOTON S.A. to Report First Half, 2024 Results on Aug 27, 2024BIOTON S.A. announced that they will report first half, 2024 results on Aug 27, 2024
New Risk • Nov 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (zł322.8m market cap, or US$77.1m).
Reported Earnings • Nov 02Third quarter 2023 earnings released: zł0.051 loss per share (vs zł0.023 loss in 3Q 2022)Third quarter 2023 results: zł0.051 loss per share (further deteriorated from zł0.023 loss in 3Q 2022). Revenue: zł50.7m (down 12% from 3Q 2022). Net loss: zł4.42m (loss widened 128% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: zł0.017 (vs zł0.017 in 2Q 2022)Second quarter 2023 results: EPS: zł0.017 (in line with 2Q 2022). Revenue: zł49.0m (up 2.1% from 2Q 2022). Net income: zł1.42m (down 2.8% from 2Q 2022). Profit margin: 2.9% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 31First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
공시 • May 26BIOTON S.A., Annual General Meeting, Jun 21, 2023BIOTON S.A., Annual General Meeting, Jun 21, 2023, at 10:00 Central European Standard Time.
Reported Earnings • May 04First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
공시 • Feb 03+ 3 more updatesBIOTON S.A. to Report First Half, 2023 Results on Aug 31, 2023BIOTON S.A. announced that they will report first half, 2023 results on Aug 31, 2023
Reported Earnings • Nov 06Third quarter 2022 earnings released: zł0.023 loss per share (vs zł0.054 profit in 3Q 2021)Third quarter 2022 results: zł0.023 loss per share (down from zł0.054 profit in 3Q 2021). Revenue: zł57.5m (up 20% from 3Q 2021). Net loss: zł1.93m (down 142% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 02Second quarter 2022 earnings released: EPS: zł0.017 (vs zł0.043 in 2Q 2021)Second quarter 2022 results: EPS: zł0.017 (down from zł0.043 in 2Q 2021). Revenue: zł48.1m (up 32% from 2Q 2021). Net income: zł1.46m (down 60% from 2Q 2021). Profit margin: 3.0% (down from 10.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
공시 • Jun 01BIOTON S.A., Annual General Meeting, Jun 30, 2022BIOTON S.A., Annual General Meeting, Jun 30, 2022, at 10:00 Central European Standard Time.
분석 기사 • Mar 21We Think BIOTON (WSE:BIO) Is Taking Some Risk With Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 45% share price gain to zł5.50, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 32x in the Biotechs industry in Poland. Total returns to shareholders of 11% over the past three years.
Reported Earnings • Nov 03Third quarter 2021 earnings released: EPS zł0.054 (vs zł0.028 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł47.8m (up 10% from 3Q 2020). Net income: zł4.61m (up 93% from 3Q 2020). Profit margin: 9.6% (up from 5.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
분석 기사 • Sep 08The Strong Earnings Posted By BIOTON (WSE:BIO) Are A Good Indication Of The Strength Of The BusinessEven though BIOTON S.A.'s ( WSE:BIO ) recent earnings release was robust, the market didn't seem to notice. We think...
Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS zł0.043 (vs zł0.08 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł36.5m (down 27% from 2Q 2020). Net income: zł3.67m (down 46% from 2Q 2020). Profit margin: 10.0% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 8% per year.
Reported Earnings • Apr 19Full year 2020 earnings released: EPS zł0.40 (vs zł1.48 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł221.8m (up 9.8% from FY 2019). Net income: zł33.9m (up zł160.6m from FY 2019). Profit margin: 15% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 22New 90-day high: zł4.64The company is up 1.0% from its price of zł4.57 on 24 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 13% over the same period.
공시 • Jan 30+ 2 more updatesBIOTON S.A. to Report Q3, 2021 Results on Oct 29, 2021BIOTON S.A. announced that they will report Q3, 2021 results on Oct 29, 2021
Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS zł0.028The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: zł43.4m (down 3.3% from 3Q 2019). Net income: zł2.39m (up zł9.73m from 3Q 2019). Profit margin: 5.5% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Is New 90 Day High Low • Sep 24New 90-day low: zł4.16The company is down 11% from its price of zł4.65 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 44% over the same period.